Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.95
Change (%)0.00 (0.00%)
Volume335,199
Data as of 10/20/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
10/17/17Verastem Pays Milestone Payment to Infinity Pharmaceuticals
BOSTON, Mass.--(BUSINESS WIRE)--Oct. 17, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc., representing the first milestone under the duvelisib license agreement between Verastem and Infinity. This milestone is based on the achievement of positive top-line results from t... 
Printer Friendly Version
10/11/17Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer
BOSTON--(BUSINESS WIRE)--Oct. 11, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of NgocDiep Le, MD, PhD, as Chief Medical Officer. Dr. Le will be responsible for overseeing the development strategy and activities for Verastem’s core assets, duvelisib and defactinib. “Diep is a highly accomplished physician-scie... 
Printer Friendly Version
09/22/17Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Sep. 22, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25th at 8:35 a.m. ET at the InterContinental New York Barclay Hotel in New York. A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. ... 
Printer Friendly Version
09/06/17Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma
Duvelisib Receives Fast Track Designation from FDA in PTCL; Company to Initiate a Phase 2 Clinical Trial by Year End 2017 Former Chief Marketing Officer, Lilly Oncology, Brian Stuglik Joins the Company’s Board of Directors Conference Call Scheduled for Today at 8:00 AM ET BOSTON--(BUSINESS WIRE)--Sep. 6, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life ... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.